Rho-Kinase-IN-2 |
| Catalog No.GC66050 |
Rho-Kinase-IN-2(화합물 23)는 경구 활성, 선택적 및 중추신경계(CNS) 침투성 Rho Kinase(ROCK) 억제제(ROCK2 IC50=3 nM)입니다. 821d96072c2d58d8970e76f526b0f6b8Rho-Kinase-IN-2는 Huntington'의 연구에 사용될 수 있습니다.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2573071-18-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC50=3 nM). Rho-Kinase-IN-2 can be used in Huntington's research[1].
Rho-Kinase-IN-2 (0-10 mM, 1 hour) treatment shows an increase in AKT phosphorylation and a decrease in MYPT1 phosphorylation[1].
Western Blot Analysis[1]
| Cell Line: | A7r5 and PANC1 cells |
| Concentration: | 0-10 mM |
| Incubation Time: | 1 hour |
| Result: | Showed concentration-dependent effects, leading to an increase in AKT phosphorylation (EC50=28 nM) and a decrease in MYPT1 phosphorylation (IC50=14 nM). |
Rho-Kinase-IN-2 (oral adiministration; 10 mg/kg; 6 times; 0.5, 1, 2, 4, 8, and 12 h) treatment shows dose- and time-dependent ROCK1 and ROCK2 target engagement[1].
Rho-Kinase-IN-2 (oral adiministration; 10 or 20 mg/kg; QD or BID; 2 weeks) treatment shows excellent tolerability assessment[1].
Rho-Kinase-IN-2 (oral adiministration; 1-20 mg/kg; once) treatment shows a direct dose- and time-dependent relationship between brain exposure and MYPT1 phosphorylation status[1].
Rho-Kinase-IN-2 (oral adiministration; 10 or 20 mg/kg; once) treatment decreases in the mean arterial, systolic, diastolic blood pressure, and heart rate[1].
Rho-Kinase-IN-2 (oral adiministration; 10 mg/kg; twice a day; 90 days) treatment leads to lower-than-expected brain concentrations[1].
| Animal Model: | Male C57BL/6 mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Oral adiministration; 10 mg/kg; 6 times; 0.5, 1, 2, 4, 8, and 12 h |
| Result: | Observed dose- and time-dependent ROCK1 and ROCK2 TE, with a free brain KiNativ ROCK1 and ROCK2 IC50=∼6 nM. |
| Animal Model: | 3-4 months old heterozygote Q175DN KI and wild-type littermate mice[1] |
| Dosage: | 10 or 20 mg/kg |
| Administration: | Oral adiministration; 10 or 20 mg/kg; once a day or twice a day; 2 weeks |
| Result: | Scored neurological index normally at all doses although a slight loss in bodyweight (∼2%) in the 20 mg/kg treatment group. |
| Animal Model: | Heterozygote HTT zQ175DN knock-in mice[1] |
| Dosage: | 1-20 mg/kg |
| Administration: | Oral adiministration; 1-20 mg/kg; once |
| Result: | Remained over MYPT1 IC50 for over 2 h of the free brain at 10 mg/kg, and observed the dose- and time-dependent inhibition of MYPT1 phosphorylation in the striatum following acute in vivo dosing. |
| Animal Model: | CD1 mice[1] |
| Dosage: | 10 and 20 mg/kg |
| Administration: | Oral adiministration; 10 or 20 mg/kg; once |
| Result: | Observed the decreases in the mean arterial (maximum change of 61.0 ± 8.5 mmHg from baseline), systolic (maximum change of 59.5 ± 8.4 mmHg from baseline), diastolic blood pressure (maximum change of 56.4 ± 9.0 mmHg from baseline), and heart rate (maximum change from predose of 107 bpm) when compared to the control group from ∼0.5 to 2 h post dose. |
| Animal Model: | Heterozygote Q175DN KI mouse model of HD[1] |
| Dosage: | 10 mg/kg |
| Administration: | Oral adiministration; 10 mg/kg; twice a day; 90 days |
| Result: | Led to lower-than-expected brain concentrations compared to single dosing. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *